Statistical power of MRI monitored trials in multiple sclerosis: new data and comparison with previous results.
OBJECTIVE
To evaluate the durations of the follow up and the reference population sizes needed to achieve optimal and stable statistical powers for two period cross over and parallel group design clinical trials in multiple sclerosis, when using the numbers of new enhancing lesions and the numbers of active scans as end point variables.


METHODS
The statistical power was calculated by means of computer simulations performed using MRI data obtained from 65 untreated relapsing-remitting or secondary progressive patients who were scanned monthly for 9 months. The statistical power was calculated for follow up durations of 2, 3, 6, and 9 months and for sample sizes of 40-100 patients for parallel group and of 20-80 patients for two period cross over design studies. The stability of the estimated powers was evaluated by applying the same procedure on random subsets of the original data.


RESULTS
When using the number of new enhancing lesions as the end point, the statistical power increased for all the simulated treatment effects with the duration of the follow up until 3 months for the parallel group design and until 6 months for the two period cross over design. Using the number of active scans as the end point, the statistical power steadily increased until 6 months for the parallel group design and until 9 months for the two period cross over design. The power estimates in the present sample and the comparisons of these results with those obtained by previous studies with smaller patient cohorts suggest that statistical power is significantly overestimated when the size of the reference data set decreases for parallel group design studies or the duration of the follow up decreases for two period cross over studies.


CONCLUSIONS
These results should be used to determine the duration of the follow up and the sample size needed when planning MRI monitored clinical trials in multiple sclerosis.
Sormani
M P
MP
Department of Neuroscience, Scientific Institute Ospedale San Raffaele, University of Milan, Italy.
Molyneux
P D
PD
Gasperini
C
C
Barkhof
F
F
Yousry
T A
TA
Miller
D H
DH
Filippi
M
M
D000293:Adolescent; D000328:Adult; D002986:Clinical Trials as Topic / Q000379:methods*; D003198:Computer Simulation; D018592:Cross-Over Studies; D005260:Female; D005500:Follow-Up Studies; D019786:Gadolinium DTPA; D006801:Humans; D007089:Image Enhancement; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D015233:Models, Statistical; D015337:Multicenter Studies as Topic / Q000379:methods; D009103:Multiple Sclerosis / Q000175:diagnosis*; D012008:Recurrence; D012107:Research Design; D018401:Sample Size; D018709:Statistics, Nonparametric
D019786:Gadolinium DTPA